Medicine & Life Sciences

1. Inflammatory Bowel Diseases 100%
2. Crohn Disease 50%
3. Ulcerative Colitis 27%
4. Population 21%
5. rhuMAb Beta7 20%
6. Practice Guidelines 19%
7. Gastroenterology 18%
8. Flax 16%
9. Canada 15%
10. Lignans 14%
11. Biological Factors 13%
12. Placebos 12%
13. Biological Therapy 12%
14. Therapeutics 12%
15. Biological Products 11%
16. Cohort Studies 11%
17. Tumor Necrosis Factor-alpha 11%
18. Inflammatory Bowel Disease 2 10%
19. Confidence Intervals 9%
20. Gastroenterologists 9%
21. Ustekinumab 9%
22. Hospitalization 9%
23. Tumor Necrosis Factor Inhibitors 8%
24. Manitoba 8%
25. Incidence 8%
26. Immunization 8%
27. Randomized Controlled Trials 8%
28. Pediatrics 8%
29. Vitamin D 8%
30. Child 7%
31. Inflammation 7%
32. Safety 6%
33. Pyruvate Kinase 6%
34. Inactivated Vaccines 6%
35. secoisolariciresinol diglucoside 6%
36. Immunosuppressive Agents 6%
37. Costs and Cost Analysis 6%
38. Practice Management 6%
39. Patient Acceptance of Health Care 6%
40. Drug Monitoring 5%
41. Immunomodulation 5%
42. Micronutrients 5%
43. Patient Reported Outcome Measures 5%
44. Venous Thromboembolism 5%
45. Biomarkers 5%
46. Physicians 5%
47. Health Care Costs 5%
48. Pharmaceutical Preparations 5%
49. Health 5%
50. Alberta 5%